Stemrim Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Genomix Co., Ltd. (to 2018)
0
Ending by 2030
Apr 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Peptide for Inducing Regeneration of Tissue and Use Thereof (US 10,364,276) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Peptide for Inducing Regeneration of Tissue and Use Thereof (US 10,550,165) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Therapeutic Agent for Cardiomyopathy, Old Myocardial Infarction and Chronic Heart Failure (US 11,969,459) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,364,276 | Peptide for Inducing Regeneration of Tissue and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,550,165 | Peptide for Inducing Regeneration of Tissue and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,623,078 | Novel Method for Treating Cardiac Infarction Using HMGB1 Fragment In force · High confidence | In force | High confidence | |
| US 9,688,733 | Novel Method for Treating Spinal Cord Injury Using HMGB1 Fragment In force · High confidence | In force | High confidence | |
| US 11,969,459 | Therapeutic Agent for Cardiomyopathy, Old Myocardial Infarction and Chronic Heart Failure In force · High confidence | In force | High confidence | |
| US 11,298,403 | Therapeutic Agent for Inflammatory Bowel Disease In force · High confidence | In force | High confidence | |
| US 12,421,498 | Ectodermal Mesenchymal Stem Cells and Method for Producing Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 2 patents in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 10 abandoned
Showing 1 to 10 of 16, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/776,908 | Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization | Jul 18, 2024 | Pending |
| 18/152,249 | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues | Jan 10, 2023 | Abandoned |
| 18/069,421 | Peptide for Inducing Regeneration of Tissue and Use Thereof | Dec 21, 2022 | Abandoned |
| 18/697,330 | Drug for Treating Fatty Liver and Nonalcoholic Steatohepatitis | Sep 30, 2022 | Pending |
| 17/517,967 | Agents for Promoting Tissue Regeneration by Recruiting Bone Marrow Mesenchymal Stem Cells And/Or Pluripotent Stem Cells into Blood | Nov 3, 2021 | Abandoned |
| 18/017,149 | Composition for Use in Treating Dystrophic Epidermolysis Bullosa | Jul 21, 2021 | Pending |
| 17/919,872 | Formulation Containing HMGB1 Partial Peptide | Apr 19, 2021 | Abandoned |
| 17/995,017 | Peptide Having Mesenchymal Stem Cell Mobilizing Activity | Apr 2, 2021 | Pending |
| 17/631,072 | Composition for Promoting Growth or Suppressing Decrease of Mesenchymal Stem Cells | Jul 30, 2020 | Abandoned |
| 16/713,202 | Peptide for Inducing Regeneration of Tissue and Use Thereof | Dec 13, 2019 | Abandoned |
10 of 16 applications shown.
Pro members see all 16 published applications.